Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Inclusion Criteria: Inclusion criterion applicable to All Groups * Subjects aged 2 to 17 years (inclusive) at enrollment * weighing at least 13 Kg at the time of enrollment Inclusion criterion applicable to Group A - Subjects at risk of meningococcal disease because of primary or secondary complement deficiencies Inclusion criterion applicable to Group B \- Subjects at risk of meningococcal disease because of functional or anatomic asplenia Inclusion criterion applicable to Group C - healthy subjects Exclusion Criteria: Exclusion criteria applicable to All Groups (A, B and C) * History of any previous immunization with a meningococcal B vaccine * History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine * Known HIV infection * History of any progressive or severe neurologic disorder or seizure disorder * Contraindication to intramuscular injection or blood drawn * Females who are pregnant, planning a pregnancy or nursing (breastfeeding) * Females of childbearing potential who have not used or do not plan to use acceptable birth control measures * History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects Exclusion criterion applicable to Groups A and B \- Previous known or suspected disease caused by N. meningitidis in the last year. Exclusion criteria applicable to Group C * Previous known or suspected d…